Advances in systemic therapy of small cell cancer of the lung

References

• Cartman ML, Muers ME. Rising incidence of SCLC in young women. Thotax54(7), 656 (1999).
   Google Scholar
• Kmietowicz Z. Women at double risk of small cell lung cancer. BE Merl" 317, 1614 (1998).
   Google Scholar
• Thompson S, Pearson MG. Changing patterns of lung cancer histology with age and gender. Thaa,Y53\(Suppl. 4), A10 (1998).
   Google Scholar
• Trillet-Lenoir VN, Arpin D, Brune J. Bone marrow metastases detection in small cell lung cancer. A review. Anticancer Res. 14(6B), 2795–2797 (1994).
   Google Scholar
• Adjei AA. Management of small cell cancer of the lung. Curl: Opin. Pulm. Merl 6, 384–390 (2000).
   Google Scholar
• ••A brief but comprehensive review of thecurrent management of small cell lung cancer.
   Google Scholar
• Pujol JL, Carestia L, Daure JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of a cisplatin-containing regimen versus a regimen without this alkylating agent. BE J. Cancer83(1), 8–15 (2000).
   Google Scholar
• ••A meta-analysis that clearly demonstrates theefficacy of cisplatin in small cell lung cancer.
   Google Scholar
• Murray N, Livingston RB, Shepherd FA et al Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J. Clin. arca 17(8), 2300–2308 (1999).
   Google Scholar
• Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versuscisplatin and etoposide versus alternation of these regimens in small cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol 10,282–291 (1992).
   Google Scholar
• •A large randomized study demonstrating that alternating 'non-cross resistant' chemotherapy was not superior to standard chemotherapy.
   Google Scholar
• Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J. Natl Cancer Inst. 83,855–861 (1991).
   PubMed Web of Science ®Google Scholar
• Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. A/4o Clin. Proc. 74(8), 809–816 (1999).
   Google Scholar
• Ettinger DS. The role of carboplatin in the treatment of small-cell lung cancer. Onco1ogy12(1 Suppl. 2), 36–43 (1998).
   Google Scholar
• Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small cell lung cancer: a Hellenic Cooperative Oncology Group study. Ann. Oncol 5,601–607 (1994).
   PubMed Web of Science ®Google Scholar
• Urban T, Chastang C, Lebas FX et al The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients: Petites Cellules' Group. Cancer 86 (11), 2238–2245 (1999).
   Google Scholar
• Yuen AR, Fuks JZ, Ettinger DS et al. Pilot study with weekly chemotherapy for patiennts with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586). Cancer 1 Li. Am. 6(1), 34–39 (2000).
   Google Scholar
• Ishihara S, Tsuchiya S, Minato K et al. A Phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer. Am. J. Clin. Oncol 23(2), 197–202 (2000).
   Google Scholar
• Postmus PE, Scagliotti G, Groen HJ et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur. I Cancer32A(9), 1498–1503 (1996).
   PubMedGoogle Scholar
• Urban T, Baleyte T, Chastang CL etal. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. Petites Cellules' Group. Lung Cancer25(2), 105–113 (1999).
   Google Scholar
• Masutani M, Ochi Y, Kaodota A et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors. Oncol Rep. 7(2), 305–310 (2000).
   PubMedGoogle Scholar
• Stewart WP, von Pawel J, Gatzemeier U et al. Effects of granulocyte-macrophage colony-stimulating factor of V-ICE chemotherapy in small-cell lung cancer: a perspective randomized study of 300 patients. J. Glitz Oncol 16(2), 642–650 (1998).
   Google Scholar
• MacNeil M, Eisenhauer EA. High-dose chemotherapy: is it standard managementfor any common solid tumor? Ann. Oncol 10(10), 1145–1161 (1999).
   Google Scholar
• •A comprehensive review of the role of high-dose chemotherapy in solid tumors.
   Google Scholar
• Fetscher S, Brugger W, Engelhardt R et al. Standard- and high-dose etoposide, ifosfamide, carboplatin and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann. Oncol 10(5), 561–567 (1999).
   Google Scholar
• Pujol JL, Douillard JY, Riviere A et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomizrd Phase III study. Clin. Oncol 15(5), 2082–2089 (1997).
   Google Scholar
• Gatzemeier U, Kleisbauer JP, Drings P et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a Phase III, multicenter, randomized study. Am. Clin. Oncol 23(4), 393–400 (2000).
   Google Scholar
• Furuse K, Fukuoka M, Nishiwaki Y et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J. Clin. Oncol 16(6), 2126–2132 (1998).
   Google Scholar
• Takahashi M, Yoshizawa H, Tanaka J et al A Phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Bone Marrow 71ansplant. 25(1), 5–11 (2000).
   Google Scholar
• Elias AD, Ayash L, Skarin AT et al. High- dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. Chest103(4 Suppl.), 433S-435S (1993).
   Google Scholar
• Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest 116(6), 531S-538S (1999).
   Google Scholar
• Elias A, Ibrahim J, Skarin AT et al. Dose- intensive therapy for limited-stage small- cell lung cancer: Long-term outcome. Clin. Oncol 17(4), 1175–1184 (1999).
   Google Scholar
• •A small study that suggests that high-dose chemotherapy may have a role in small cell lung cancer.
   Google Scholar
• Aapro MS. Oral etoposide and palliative treatment for small-cell lung cancer. Lancet 348(9027), 559 (1996).
   PubMedGoogle Scholar
• Carney DN, Grogan L, Smit EF, Harford P, Berendsen 1111, Pastmus PE. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin. Oncol 17(1 Suppl. 2), 49–53 (1990).
   Google Scholar
• Grunberg SM. Cyclophosphamide and etoposide for non-small cell and small cell lung cancer. Drugs 58\(Suppl. 3), 11–15 (1999).
   Google Scholar
• Samantas E, Skarlos DV, Pectasides D et al. Combination chemotherapy with low doses of weekly carboplatin and oral etoposide in poor risk small cell lung cancer. Lung Cancer23(2), 159–168 (1999).
   PubMedGoogle Scholar
• Matsui K, Masuda N, Fukuaka M et al Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. BE j Cancer 77(11), 1961–1965 (1998).
   Google Scholar
• Ardizzoni A, Pennucci C, Fusco V et al. Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide. Anticancer Res. 9(4), 937–939 (1989).
   PubMedGoogle Scholar
• Souhami RL, Spiro SG, Rudd RM et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. j Natl Cancer Inst. 89 (8), 577–580 (1997).
   PubMedGoogle Scholar
• Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicenter randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348 (9027), 563–566 (1996).
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated conclusively thatsingle-agent oral etoposide is inferior to iv. multidrug therapy.
   Google Scholar
• Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell cancer: perceptible progress. j Clin. Oncol 17(6), 1794–1801 (1999).
   Google Scholar
• •An overview of all US cooperative group trials in extensive stage SCLC from 1972-1993.
   Google Scholar
• Huisman C, Postmus PE, Giaccone G. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Brat. Rev 25(4), 199–206 (1999).
   Google Scholar
• Kelly K. New chemotherapy agents for small cell lung cancer. Chest 117(4 Suppl.), 156S-162S (2000).
   Google Scholar
• Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology54(6A Suppl.), 22–29 (1999).
   Google Scholar
• Tishler RB, Schiff PB, Geard CR. Taxol: A novel radiation sensitizer. int. j Radiat. Oncol Biol. Phys. 22(3), 613–617 (1992).
   Google Scholar
• Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. j Clin. Oncol 13(6), 1430–1435 (1995).
   Google Scholar
• Kirschling RJ, Grill JP, Marks RS et al Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a Phase II study of the North Central Cancer Treatment Group. Ainj Clin. Oncol. 22 (5), 517–522 (1999).
   Google Scholar
• Ettinger DS. Concurrent paclitaxel- containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin. Radiat. Oncol. 9(2 Suppl. 1), 148–150 (1999).
   Google Scholar
• Strauss GM, Lynch TJ, Elias AD et al. Ifosfamidekarboplatinietoposideipaclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin. Oncol 24(4 Suppl. 12), S12-73—S12-80 (1997).
   Google Scholar
• Sonpavde G, Ansari R, Walker P et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A hoosier oncology group trial. Ainj Clin. Oncol 23(1), 68–70 (2000).
   Google Scholar
• Gatzemeier U, Jagos U, Kaukel E, Koschel G, von Pawel J. Paclitaxel, carboplatin and oral etoposide: a Phase II trial in limited-stage small cell lung cancer. Semin. Oncol 24(4 Suppl. 12), S12-149—S112-152 (1997).
   Google Scholar
• Neill FIB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR. A Phase II study evaluating the efficacy of carboplatin, etoposide and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin. Oncol 24(4 Suppl. 12), S12-130—S112-134 (1997).
   Google Scholar
• Hainsworth JD, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin and extended-schedule oral etoposide for small- cell lung cancer. Oncology12(1 Suppl. 2), 31–35 (1998).
   Google Scholar
• Glisson BS, Kurie JM, Perez-Soler R et al. Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. j Clin. Oncol. 17 (8), 2309–2315 (1999).
   Google Scholar
• •A small study with impressive response rates. This regimen is in Phase III trials.
   Google Scholar
• Bunn PA, Kelly K. A Phase I study of cisplatin, etoposide and paclitaxel in small cell lung cancer. Semin. Oncol 24(4 Suppl. 12), S12-144—S112-148 (1997).
   Google Scholar
• Levitan N, Dowlati A, Shina D et al. Multi- institutional Phase VII trial of paclitaxel, cisplatin and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. Clin. Oncol. 18(5), 1102–1109 (2000).
   Google Scholar
• Birch R, Weaver CH, Hainsworth JD, Bobo C, Greco FA. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Semin. Oncol. 24(4 Suppl. 12), S12-135—S112-137 (1997).
   Google Scholar
• Kelly K, Pan Z, Wood ME, Murphy J, Bunn PAJ. A Phase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer. Clin. Cancer Res. 5(11), 3419–3424 (1999).
   Google Scholar
• •A small Phase I study with impressive response rates. This regimen is in Phase III trials.
   Google Scholar
• Groen HJ, Fokkema E, Biesma B et al. Paclitaxel and carboplatin in the treatment of small—cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: a non-cross-resistant schedule. Clin. Oncol 17(3), 927–932 (1999).
   Google Scholar
• Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA. Phase II study of docetaxel (taxotere) in patients with previously untreated extensice small cell lung cancer. Invest. New Drugs 13(4), 343–345 (1996).
   PubMedGoogle Scholar
• Chen YM, Perng RP, Yang KY et al Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. Chung • Hua i Hsueh Tsa Chih-Chinese Medical Journal63(8), 605–611 (2000).
   Google Scholar
• Smyth JF, Smith IE, Sessa C et al Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group. Eur. Cancer30A(8), 1058–1060 (1994).
   Google Scholar
• Hesketh PJ, Crowley JJ, Burris HAR et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group Phase II trial. Cancer' Sci. Am. 5(4), 237–241 (1999).
   Google Scholar
• Higano CS, Crowley JJ, Veith RV, Livingston RB. A Phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, Southwest Oncology Group study. Invest Aim / Drugs 15(2), 153–156 (1997).
   PubMedGoogle Scholar
• Furuse K, Kubota K, Kawahara M et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology53 (2), 169–172 (1996).
   PubMedGoogle Scholar
• Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer. Eur. j Cancer 29A(12), 1720–1722 (1993).
   Google Scholar
• Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol 23(1 Suppl. 3), 3–10 (1996).
   Google Scholar
• von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cydophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Oncol 17(2), 658–667 (1999). Pivotal study that led to the approval of topotecan for the treatment of relapsed SCLC.
   Google Scholar
• Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs58(3), 533–551 (1999).
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombemowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office and the Lung Cancer Cooperative Group. Clin. Oncol 15(5), 2090-2096 (1997).
   Google Scholar
• Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydorxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Phatmacol 52(7), 1103–1111 (1996).
   Google Scholar
• Nakanishi Y, Takayama K, Takano K et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am. J Clin. Oncol 22(4), 399–402 (1999).
   Google Scholar
• Fukuda M, Nishio K, Kanzawa F et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 56(4), 789–793 (1996).
   Google Scholar
• Pei XH, Nakanishi Y, Bai F et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 8 (3), 231–237 (1998) .
   Google Scholar
• Fugita A, Takabatake H, Tagaki S, Sekine K. Combination of cisplatin, ifosfamide and irinotecan with rhG-CSF support for the tratment of refractory or relapsed small-cell lung cancer. Oncology59(2), 105–109 (2000).
   PubMedGoogle Scholar
• Negoro S, Noda K, Nishiwaki Y et al. A randomized Phase III study of irinotecan and cisplatin versus etoposide and cisplatin in extensive disease small cell lung cancer. Lung Cancer 29 (Suppl. 1), 95 (2000) (Abstract) . This preliminary report in abstract form, promises the first regimen in 20 years that is superior to etoposide and cisplatin. The study is being confirmed in the USA.
   Google Scholar
• Postmus PE, Schramel FM, Smit EE Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. Semin. Oiled 25(4 Suppl. 9), 79–82 (1998).
   Google Scholar
• Cormier Y, Eisenhauer E, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol 5(3), 283–285 (1994).
   Google Scholar
• Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In VitIO cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Brj Cancer 75 (6), 869–877 (1997) .
   PubMed Web of Science ®Google Scholar
• Bahadori HR, Lima CM, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 19(6B), 5423–5428 (1999).
   Google Scholar
• Earle CC, Stewart DJ, Cormier Y et al. A Phase I study of gemcitabine/cisplatin/ etoposide in the treatment of small-cell lung cancer. Lung- Cancer 22 (3), 235–241 (1998) .
   PubMedGoogle Scholar
• Rassmann I, Thodtmann R, Depenbrock H et al. Gemcitabine and etoposide in small cell lung cancer: Phase land II trials. Semin. Oncol 24(2 Suppl. 7), S7-75—S77-78 (1997).
   Google Scholar
• Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: Biology and molecular biology come of age. Chest 117(4 Suppl. 1), 1635–1685 (2000).
   Google Scholar
• Chaudhry A, Carrasquillo JA, Avis IL et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin. Cancer Res. 5(11), 3385–3393 (1999).
   PubMedGoogle Scholar
• MacKinnon AC, Armstrong RA, Waters CM et al. [Arg6,D-Trp7,9,NmePhe81-substance P (6–11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Br. Cancer80(7), 1026–1034 (1999).
   Google Scholar
• Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 5(10), 2773–2779 (1999).
   Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long term survival of patients with small cell lung cancer agter adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmetter-Guerin. Clin. Cancer Res. 5 (6), 1319–1323 (1999). Demonstration of prolongation of time-to-progression in this proof-of-principle study in SCLC patients who have completed standard therapy.
   Google Scholar
• Prior C, Oroszy S, Oberaigner W et al. Adjunctive interferon-a-2c in stage IIIB/IV small-cell lung cancer: a Phase III trial. Eta: Respr. 10(2), 392–396 (1996).
   Google Scholar
• Routsalainen T, Halme M, Isokangas 0-P et al. Interferon-a and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer: a feasibility study. Anticancer Drugs 11, 101–108 (2000).
   PubMedGoogle Scholar
• Ruotasalainen TM, Halme M, Tamminen K et al. Concomitant chemotherapy and IFN-a for small cell lung cancer: a randomized multicenter Phase III study. J. Interferon Cytokine Res. 19(3), 253–259 (1999).
   PubMedGoogle Scholar
• Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH, Mabry M. A Phase II study of all- trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer 83(6), 1102–1108 (1998).
   PubMedGoogle Scholar
• Michael M, Babic B, Khkha R et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. 1 Clin. Oncol 17(6), 1802–1808 (1999).
   Google Scholar
• Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetics studyof bc1-2 antisense oligonucleotide therapyin patients with non-Hodgkin's lymphoma.Clin. Oncol 18(9), 1812–1823 (2000).
   Google Scholar
• Catzavelos C, Bhattacharya N, Ung YC et al Decreased levels of the cell-cycle inhibitors p27Kipl protein: prognostic implication in primary breast cancer. Nature Merl 3(2), 227–230 (1997).
   Google Scholar
• Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Natl Cancer Inst. 88(20), 1442–1455 (1996).
   Google Scholar
• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387(6630), 296–299 (1997).
   Google Scholar
• Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Merl 3(2), 231–234 (1997).
   Google Scholar
• Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 13(18), 2375–2387 (1999).
   Google Scholar
• Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin DI phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11(8), 957–972 (1997).
   Google Scholar
• Banerjee P, Ahmad ME, Grove JR, Kozlosky C, Price DJ, Avruch J. Molecular structure of a major insulin/mitogen-activated 70 kDa S6 protein kinase. Proc. Nati Acad. Sci. USA 87(21), 8550–8554 (1990).
   Google Scholar
• Chung J, Grammer TC, Lemon IKP, Kazlaukas A, Blenis J. PDGR-and insulin-dependent pp70S6k activation mediated by phosphatidylinosito1-3-0H kinase. Nature 370(6484), 71–75 (1994).
   Google Scholar
• Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p7026k phosphorylation, cell proliferation and colony formation in small cell lung cancer cells. Cancer Res. 56(17), 3895–3897 (1996).
   Google Scholar
• Jackson RJ, Wickens M. Translational controls impinging on the 5'-untranslated region and initiation factor proteins. CI.117: Opin. Genet. Dev 7(2), 233–241 (1997).
   Google Scholar
• Lawrence JCJ, Abraham RT. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trend's Biochem. Sci. 22(9), 345–349 (1997).
   Google Scholar
• Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Nati Acad. Li. USA 95(4), 1432–1437 (1998).
   Google Scholar
• Sonenberg N, Gingras AC. The mRNA 5' cap-binding protein eIF4E and control of cell growth. C1117: Opin. Cell Biol. 10(2), 268–275 (1998).
   Google Scholar
• Adjei AA. Blocking oncogenic ras signaling for cancer therapy. j Natl Cancer Inst. 93, (2001) (In Press).
   Google Scholar
• •A comprehensive review of novel anticancer drug targets in the ras signaling pathway.
   Google Scholar
• Gemba K, Ueoka H, Kiura K, Tabata M, Harada M. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer29(1), 23–31 (2000).
   Google Scholar
• Dingemans AM, Witlox MA, Stallaert RA, Postmus PE, Giaccone G. Expression of DNA topoisomerase II a and topoisomerase II 3 genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res. 5(8), 2048–2058 (1999).
   Google Scholar
• Johnson BE, Brennan JF, Ihde DC, Gazdar AF myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. j Natl Cancer Inst. 13,39–43 (1992).
   Google Scholar
• Kaseda S, Ueda M, Ozawa S, Ishihara T, Abe 0, Shimizu N. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. I Surg. Oncol 42(1), 16–20 (1989).
   Google Scholar
• Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res. 52(11), 3089–3093 (1992).
   PubMedGoogle Scholar
• Maitra A, Amirkhan RII, Saboorian MET, Frawley WH, Ashfaq R. Survival in small cell lung carcinoma is independent of Bc1-2 expression. Hum. Pathol 30(6), 712–717 (1999).
   Google Scholar
• Kaiser U, Schilli M, Haag U et al. Expression of bc1-2--protein in small cell lung cancer. Lung Cancer 15 (1), 31–40 (1996).
   Google Scholar
• Saresvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Catrinogenesis 20(8), 1649–1651 (1999).
   Google Scholar
• Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human p19ARF protein encoded by the beta transcript of the pl6INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 58(17), 3926–3931 (1998).
   Google Scholar
• Helm n K, Holm K, Niebuhr A et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/ preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60 (7), 1949–1960 (2000).
   Google Scholar
• Dennis TR, Stock AD. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in viva Clin. Cancer Res. 4(11), 2849–2858 (1998).
   Google Scholar
• Ueoka H, Tabata M, Kiura K et al. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a Phase I study. Br. Cancer 79(5-6), 984–990 (1999).
   Google Scholar
• Grozea PN, Crowley JJ, Canfield VA et al. Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer 80(6), 1029–1033 (1997).
   Google Scholar
• Schiller JH, Kim K, Hutson P, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. j Clin. 0=1 14(8), 2345–2352 (1996).
   Google Scholar
• Higano CS, Crowley JJ, Veith RV, Livingston RB. A Phase II trial of intravenous vinorelbine in previously untreated patients with extensive cmall cell lung cancer, Southwest Oncology Group study. Invest. New Drugs 15 (2), 153–156 (1997).
   PubMedGoogle Scholar